Advancing Prognostic Biomarkers in Pulmonary Arterial Hypertension: The Role of Plasma Immunoglobulin G Fucosylation

Pulmonary arterial hypertension (PAH) is a devastating disease characterized by progressive increase in pulmonary vascular resistance and mean pulmonary artery pressure, ultimately leading to right heart failure [1, 2]. Despite advancements in our understanding of pathophysiology of PAH, predicting patient outcomes remains a significant challenge [3]. Current risk assessment approaches in PAH rely on a multidimensional evaluation that incorporates clinical, functional, exercise, biochemical, and hemodynamic parameters [3]. While the only circulating biomarker included in established prognostic models is B-type natriuretic peptide (BNP) or its precursor, N-terminal pro BNP (NT-pro BNP). However, these biomarkers do not fully capture the complexity of PAH pathophysiology, which involves immune dysregulation and inflammation [4, 5]. In this context, the study by Zhang et al., published in the Journal of the American College of Cardiology, represents a significant advancement by identifying plasma immunoglobulin G (IgG) N-glycome traits as novel prognostic biomarkers for PAH [6]. The study primarily focuses on IgG fucosylation, a specific glycosylation trait of IgG molecules. Glycosylation, the attachment of sugar moieties to proteins, is a critical post-translational modification that influences protein function and stability. Aberrant glycosylation has been implicated in numerous diseases, including cardiovascular disorders [7-10]. In IgG, N-glycans attached to the Fc region modulate immune responses, including antibody-dependent cellular cytotoxicity. The authors hypothesized that specific IgG N-glycan traits could reflect underlying pathophysiological processes in PAH and serve as an independent prognostic indicator. To test this, the authors profiled plasma IgG N-glycomes using mass spectrometry in a cohort of 622 PAH patients. Their results revealed that low IgG fucosylation levels were significantly associated with increased mortality, independent of established risk factors such as age, sex, and NT-pro BNP levels. This collaborative study by two national centers, Beijing and Shanghai, China, provides compelling evidence that IgG fucosylation is an independent predictor of survival in PAH and significantly enhances existing risk assessment models. The study's methodology is noteworthy for its rigor and comprehensiveness. This is the first IgG N-glycomic study in PAH, marking a new investigative area in the field. Using a high-throughput mass spectrometry approach ensured accurate and reproducible glycan profiling [11, 12]. Plasma IgG N-glycosylation was measured using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to profile N-glycan traits such as galactosylation and fucosylation. Reliability was ensured with technical replicates. Derived traits were calculated for better interpretation, and statistical analyses, including Cox regression, assessed prognostic value while adjusting for confounders. The study's robust validation, including discovery (Beijing cohort), validation (Shanghai cohort), and random sampling analysis (combined cohorts), strengthens the credibility of its findings. The prognostic value of IgG fucosylation was consistent across subgroups stratified by sex and treatment strategies, demonstrating its independent influence. Moreover, the integration of IgG fucosylation into existing risk models improved their predictive capacity, as evidenced by an increase in Harrell C-indexes. This suggests that IgG fucosylation provides additional prognostic information beyond traditional risk factors. Clinicians could use this biomarker to better stratify patients, particularly those in the intermediate-risk category, allowing for more personalized treatment strategies. The study's implications extend beyond PAH. Glycosylation changes have been implicated in various cardiovascular diseases, highlighting the broader potential of IgG N-glycans as biomarkers. Their stability under various storage conditions is advantageous for clinical application, minimizing potential biases from sample degradation [7-11]. Despite its strengths, the study has limitations that warrant consideration. The cohorts were derived from idiopathic and heritable PAH, and it remains to be seen whether the findings are generalizable to other subtypes of PAH or to other cardiovascular diseases. While the study establishes an association between IgG fucosylation and survival, the confounding factors should be more thoroughly controlled and the underlying mechanisms remain to be elucidated. Additionally, how does IgG fucosylation change over the course of disease progression or in response to treatment? Longitudinal studies could elucidate its potential as a marker of treatment response or disease activity. Future research should explore the biological pathways linking IgG glycosylation to PAH pathophysiology, which could uncover new therapeutic targets. In conclusion, the study by Zhang et al. represents a significant step forward in the quest for reliable prognostic biomarkers in PAH, expanding the repertoire of biomarkers beyond traditional options like BNP or NT-pro BNP. By identifying plasma IgG fucosylation as a robust predictor of survival, the research provides an additional tool for risk assessment and patient management. The integration of IgG fucosylation allows for a more nuanced differentiation in risk stratification among PAH patients, facilitating more precise treatment approaches tailored to individual risk profiles. As the field of glycomics continues to evolve, it holds promise for transforming our understanding and treatment of complex diseases like PAH. The integration of glycan biomarkers into clinical practice could herald a new era of precision medicine, ultimately improving patients' outcomes and quality of life. All authors took part in drafting and revising the article, and all authors approved the final version to be published. Qianwen Wu: writing – original draft, methodology, visualization. Huangshu Ye: writing – original draft, methodology, visualization. Zhangdi Zhou: data curation, investigation, validation. Dongyu Li data curation, investigation, validation. Miaojia Zhang: supervision, writing – review and editing. Xiaoxuan Sun: supervision, writing – review and editing. Qiang Wang: supervision, writing – review and editing. The authors declare no conflicts of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.